• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Pediatrics . Possible In-Utero Transmission of SARS-CoV-2 and Severe Respiratory Disease in a Preterm Infant

tetano

Editor, Senior Moderator
Pediatrics


. 2022 Apr 15.
doi: 10.1542/peds.2021-054557. Online ahead of print.
Possible In-Utero Transmission of SARS-CoV-2 and Severe Respiratory Disease in a Preterm Infant


Paul Fleming[SUP] 1 2 [/SUP], Sujith Pereira[SUP] 1 2 [/SUP], Olga Kapellou[SUP] 1 [/SUP], Alleyna Claxton[SUP] 3 [/SUP], Alasdair Bamford[SUP] 4 5 [/SUP], Narendra Aladangady[SUP] 1 2 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are uncommon in newborn infants. This report describes possible in-utero transmission of the B.1.1.7 (Alpha) variant in a preterm infant born at 31 weeks' gestational age who presented with severe respiratory disease. The infant was treated with high frequency oscillatory ventilation, antiviral medications and corticosteroids and transitioned to non-invasive respiratory support on day 33. By day 63, she was off positive pressure support and breathing room air and she was discharged home on day 70. She demonstrated normal growth and development at a 6-month follow-up visit. Placental histopathology revealed placentitis characterised by loss of intervillous spaces due to fibrin deposition and inflammatory cell infiltration. Optimum management strategies for treating infants with severe respiratory SARS-CoV-2 infection have yet to be determined.
 
Back
Top Bottom